Pregnancy Outcomes After Semaglutide Exposure

Abstract

Semaglutide, a GLP1 agonist, is used for glycemic control in Type 2 diabetes and weight management [1]. In animals (mice, rats and rabbits), GLP1 agonists is associated with embryofetal mortality, structural abnormalities and growth disturbances concerning delayed ossification and skeletal variants [2]. A recent cohort study on the potential risk of malformations included GLP-1 receptor agonists but did not provide specific estimates for semaglutide [3]. Except for case reports, there are no studies on other pregnancy outcomes [1, 4, 5].

Unintentional use of semaglutide in pregnancy is rapidly increasing. Women who experience such exposure are difficult to advise due to the lack of human data. We report pregnancy and neonatal outcomes of pregnancies exposed to semaglutide based on data from a cohort of over 100 000 pregnancies.

The study population included all singleton pregnancies surviving the first trimester in the Central Denmark Region, which accounts for one fifth of Denmark's population. This encompassed pregnancies from a gestational age (GA) of 12 + 0/7 weeks onwards, with conception dates ranging from 1 June 2016 to 22 June 2023, regardless of foetal survival. In Denmark, there is universal access to healthcare free of charge.

Data were collected from the electronic charts from all hospitals in the region and linked on the individual level, including exact mother–child linkage, via a unique identifier from the Danish Civil Registration System.

Exposure to semaglutide (ATC A10BJ06) and/or insulin (ATC A10B) in first trimester (from the estimated conceptiondate to 70 days after, corresponding to GA 12 + 0/7), pregnancy and neonatal outcomes and informations regarding diabetes were collected from the electronic patient record.

Major malformations were classified according to EUROCAT classification including both prenatal (ultrasound data) and postnatal registered malformations as previously reported, with a deviation with reverse registration of congenital malformations (DQ) diagnoses found later in life (until June 2024) [6]. The neonatal outcomes of respiratory distress syndrome (RDS), hypoglycemia and jaundice were identified using ICD10 codes (RDS DP220, 228, 229/hypoglycemia DP703, 704/jaundice DP550, 551, 558-560, 569, 570, 578-585, 588-593, 598, and 599). The outcomes of semaglutide-exposed pregnancies were compared to pregnancies exposed to either insulin or no diabetes medication.

Statistical analyses were performed with Stata (Stata Corp, College Station, TX, United States).

Wilcoxon ranksum test was used for numerical data and Fishers exact test for dichotomous data.

Access to the data was approved according to Danish legislation (Sundhedsloven §46, permission [1-45-70-88-22, 5 April 2024]), and data were stored according to the EU GDPR rules.

The study was conducted in accordance with the Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical studies [7].

The population included 104 422 singleton pregnancies. Of these, 32 were exposed to semaglutide during the first trimester: 27 used Ozempic (22 of these in combination with insulin), and five used Wegovy. Seventeen discontinued semaglutide in the first trimester, and 14 used semaglutide throughout all trimesters. The insulin comparison group included 547 pregnancies with no simultaneous use of semaglutide. The semaglutide-exposed group was older and had a higher prepregnancy BMI than the two comparison groups (Table 1).

There was no increased risk of major malformations among semaglutide-exposed pregnancies compared to insulin-exposed or unexposed pregnancies (Table 2). Semaglutide-exposed pregnancies had a higher risk of preterm birth, large for gestational age (LGA), neonatal hypoglycemia and jaundice compared to unexposed pregnancies, but the risks were similar to those in insulin-exposed pregnancies (Table 2).

Semaglutide exposure was not associated with an increased risk of major malformations, but the analyses were based on only 32 exposed pregnancies with limited power. Compared to unexposed, semaglutide was associated with increased risks of preterm birth, LGA, neonatal hypoglycemia and jaundice. However, semaglutide was not associated with these outcomes when compared to pregnancies exposed to insulin, possibly reflecting that most semaglutide exposed also used insulin, were older and had a higher BMI.

The main limitation was that only 32 were exposed to semaglutide. Due to the small number of exposed individuals, it was not possible to adjust for potential confounders.

It is likely that the use of semaglutide among women without diabetes will increase. In our data, the first 27 exposed were Ozempic (2019–2023) and the five recent were women without diabetes with Wegovy exposure (2023). We speculate that unintended use of semaglutide in early pregnancy may increase proportionally to the increased use of semaglutide for weight loss, which may increase fertility among women with overweight. Further, maternal weight gain after discontinuation of semaglutide may per se cause obstetric complications.

In conclusion, 32 pregnancies exposed to semaglutide and insulin showed comparable risks of malformations, preterm birth, LGA, neonatal hypoglycemia and jaundice compared to pregnancies exposed solely to insulin. Given the current knowledge gaps and the limited availability of both animal and human studies, it remains unsafe to revise the recommendation against use during pregnancy. Unintended use of semaglutide during pregnancy is likely to increase, and larger studies are needed.

The authors declare no conflicts of interest.